Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHENNONG real-world study of Repatha plus standard of care in Chinese ASCVD patients
ChiCTR2400088942Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in atherosclerotic disease, myocardial infarction (MI), ischemic stroke and 2 more (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Composite major cardiovascular events (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization). Started Aug 2022; status: recruiting.
02
Drugs
evolocumab
03
Conditions
atherosclerotic diseasemyocardial infarction (MI)ischemic strokearteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400088942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088942.